0000000000229072

AUTHOR

Gabriele Simonini

showing 15 related works from this author

Proceedings Of The 23Rd Paediatric Rheumatology European Society Congress: Part Two

2017

lcsh:Diseases of the musculoskeletal systemlcsh:RJ1-570lcsh:Pediatricslcsh:RC925-935Meeting Abstracts
researchProduct

Are Kawasaki Disease and Pediatric Multi-Inflammatory Syndrome Two Distinct Entities? Results from a Multicenter Survey During SARS-CoV-2 Epidemic in…

2020

Background: There is mounting evidence on the existence of a childhood multi-inflammatory syndrome related to SARS-CoV-2, sharing similarities with Kawasaki Disease (KD).  Methods: On April 24th,2020 the Rheumatology Study Group of the Italian Pediatric Society launched a survey to enroll patients diagnosed with KD or KD-like disease. Classification was: 1) classical and incomplete KD, named Kawasaki Disease Group (KDG); 2) KD-like multi-inflammatory syndrome, named KawaCOVID Group (KCG). Demographic, clinical, and laboratory data, treatment information, and patients’ outcome were collected in an online anonymized database (RedCAPO). Chi square test or exact Fisher test and non parametric W…

medicine.medical_specialtyMyocarditisHeart malformationbusiness.industryDiseasemedicine.diseaseInstitutional review boardsymbols.namesakeInternal medicineCohortChi-square testsymbolsMedicineKawasaki diseasebusinessFisher's exact testSSRN Electronic Journal
researchProduct

Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort

2021

Abstract Objective The objective of this study was to use real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with systemic JIA (sJIA). Methods A retrospective multicentre study of children with sJIA was performed. Clinical features, laboratory parameters and adverse events were collected at baseline, and 6 and 12 months after starting canakinumab. The primary outcome measure of effectiveness was clinically inactive disease (CID) off glucocorticoids (GCs) treatment at 6 months. Results A total of 80 children from 15 Italian centres were analysed. Of the 12 patients who started canakinumab in CID while receiving anakinra, all maintained CID. Of the 68 …

medicine.medical_specialtyMultivariate analysissystemic juvenile idiopathic arthritisArthritisJuvenileAntibodies Monoclonal HumanizedcanakinumabAntibodiessystemic juvenile idiopathic arthritis.Settore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicineMonoclonalmedicinecanakinumab; clinically inactive disease; systemic juvenile idiopathic arthritis; Antibodies Monoclonal Humanized; Child; Glucocorticoids; Humans; Retrospective Studies; Arthritis Juvenile; Macrophage Activation SyndromeHumanscanakinumab clinically inactive disease systemic juvenile idiopathic arthritis Antibodies Monoclonal Humanized Child Glucocorticoids Humans Retrospective Studies Arthritis Juvenile Macrophage Activation SyndromePharmacology (medical)clinical inactive disease.Adverse effectChildHumanizedGlucocorticoidsRetrospective StudiesUnivariate analysisAnakinrabusiness.industryclinically inactive diseaseArthritisMacrophage Activation Syndromemedicine.diseaseArthritis JuvenileCanakinumabMacrophage activation syndromeCohortSystemic juvenile idiopathic arthritibusinessmedicine.drug
researchProduct

Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one

2017

lcsh:Diseases of the musculoskeletal systemlcsh:RJ1-570lcsh:Pediatricslcsh:RC925-935Meeting Abstracts
researchProduct

The impact of the Eurofever criteria and the new Infevers MEFV classification in real life: results from a large international FMF cohort

2022

INTRODUCTION: New Eurofever/PRINTO classification criteria (EPCC) for Familial Mediterranean Fever (FMF) and other recurrent fevers have been recently developed, together with the classification of the pathogenicity of MEFV variants. OBJECTIVES: To evaluate the impact in real life of both the EPCC and INSAID pathogenicity classification of MEFV variants in the large international Eurofever FMF cohort. METHODS: Baseline demographic, genetic and clinical data of FMF patients included in the Eurofever registry were evaluated. The EPCC and the 2018 INSAID classification for MEFV variants were applied in all eligible FMF patients. RESULTS: Since November 2009, clinical information was available …

Male*Genetic analysis*Autoinflammatory diseasesPyrinFamilial Mediterranean fever*Classification criteriaCohort StudiesAnesthesiology and Pain MedicineRheumatologySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAMutation*Familial mediterranean feverHumansFemale*RegistryRegistriesAutoinflammatory diseases Classification criteria Familial mediterranean fever Genetic analysis Recurrent fevers Registry Cohort Studies Colchicine Female Humans Male Mutation Pyrin Registries Familial Mediterranean FeverColchicine*Recurrent fevers
researchProduct

Increased Percentages of Tumor Necrosis Factor-α+/Interferon-T+Lymphocytes and Calprotectin+/Tumor Necrosis Factor-A+ Monocytes in Patients with Acut…

2012

In vivo exposure to microorganisms resident in the oral cavity is considered as a possible cause of Kawasaki disease (KD), and some epitopes derived from streptococci display homology with Factor H of Complement. Additionally, calprotectin, a major calcium binding protein released by neutrophils and activated monocytes, could be directly involved in endothelial damage occurring in KD. The aim of our study is to evaluate the percentages of IFN-γ+ and/or TNF-α+ lymphocytes and double positive calprotectin/TNF-α monocytes (CD14+) after in vitro stimulation with streptococcal- and/or Factor H-derived peptides, in patients with acute KD. Peripheral Blood Mononuclear Cells (PBMCs) obtained from …

Pharmacologybusiness.industryImmunologymedicine.diseaseEpitopeInterferonIn vivoImmunologymedicineImmunology and AllergyIn patientKawasaki diseaseTumor necrosis factor alphaCalprotectinbusinessTumor necrosis factor αmedicine.drugInternational Journal of Immunopathology and Pharmacology
researchProduct

Transitional care of young people with juvenile idiopathic arthritis in Italy: results of a Delphi consensus survey

2018

OBJECTIVES: To present the results of a Delphi consensus survey among Italian paediatric and adult rheumatologists on transitional care (TC) of young people (YP) with juvenile idiopathic arthritis (JIA). METHODS: A taskforce of 27 paediatric and adult rheumatologists evaluated the applicability of the 2016 EULAR/PReS recommendations for TC to the Italian rheumatology practice and healthcare system and formulated additional country-specific statements aimed to increase their suitability. After a two-round discussion, applicability of EULAR/PReS recommendations and agreement with newly-proposed statements were voted on a 0-10 scale (where 0 = no applicability/agreement and 10 = total applicab…

AdultTransition to Adult CareSettore MED/16 - REUMATOLOGIApaediatric rheumatic diseasesConsensusAdolescentJuvenileSocio-culturaleAdolescent; Adult; Child; Consensus; Humans; Italy; Surveys and Questionnaires; Arthritis Juvenile; Rheumatology; Transition to Adult Care; Transitional Carejuvenile idiopathic arthritis paediatric rheumatic diseases Delphi survey recommendations transitional care young peopleAdolescent Adult Child Consensus Humans Italy Surveys and Questionnaires Arthritis Juvenile Rheumatology Transition to Adult Care Transitional Careyoung peopleSettore MED/38 - Pediatria Generale E Specialisticayoung peopleAdolescentRheumatologySurveys and QuestionnairesHumansChildLS7_9ArthritisTransitional CareArthritis JuvenileItalyrecommendationsjuvenile idiopathic arthritisDelphi surveyjuvenile idiopathic arthritis paediatric rheumatic diseases Delphi survey recommendations transitional care young people
researchProduct

Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal s…

2021

Familial Mediterranean fever (FMF) is characterized by self limited episodes of fever and polyserositis.1 MEFV gene en codes for a protein named Pyrin, which plays a pivotal role in the activation and secretion of IL-1.2 Daily colchicine is highly effective in preventing attacks in this disorder in a dose-related fashion.3 Many definitions of colchicine resistance are available in the literature. The European League Against Rheumatism (EULAR) guidelines defined resistance as one or more attacks per month in compliant patients who had been receiving the maxi mally tolerated dose for at least 6 months.4 A similar definition was confirmed by a recent consensus among experts.5 In the present na…

Longitudinal studybusiness.industryFamilial Mediterranean feverInterleukinDiseaseFamilial Mediterranea fevermedicine.diseaseSymptom Flare UpColchicine; Humans; Interleukin 1 Receptor Antagonist Protein; Longitudinal Studies; Symptom Flare Up; Familial Mediterranean FeverPersistence (computer science)Familial Mediterranean Feverchemistry.chemical_compoundInterleukin 1 Receptor Antagonist ProteinSettore MED/38 - Pediatria Generale E SpecialisticachemistryColchicine Humans Interleukin 1 Receptor Antagonist Protein Longitudinal Studies Symptom Flare Up Familial Mediterranean FeverImmunologyCOLCHICINE RESISTANCEImmunology and AllergyMedicineColchicineHumansLongitudinal StudiesbusinessColchicine
researchProduct

Increased percentages of calprotectin and TNF-Α double-positive monocytes in the acute phase of Kawasaki disease

2011

Background The acute phase of KD is characterized by a deficiency of suppressor T cells, marked activation of the immune system and increased secretion of cytokines by immune effector cells. Moreover, it has been shown that myeloid-related protein (MRP-8 and MRP-14) and S100proteins, the major calcium-binding proteins secreted by activated neutrophils and monocytes, contribute to cause inflammation in acute lesions of KD, and indeed one of the more common hematological alteration in KD is the increase of peripheral blood monocytes. Calprotectin, one of the major calcium-binding proteins, can lead to direct and indirect effects that result not only in inflammation but also in modification of…

Pediatricsmedicine.medical_specialtylcsh:Diseases of the musculoskeletal systemDouble negativeInflammationTNF alfa CalprotectinImmune systemSettore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicineImmunology and AllergyMedicineSecretionPediatrics Perinatology and Child HealthKawasaki Diseasebusiness.industrylcsh:RJ1-570lcsh:Pediatricsmedicine.diseaseRheumatologyPediatrics Perinatology and Child HealthImmunologyOral PresentationKawasaki diseaselcsh:RC925-935Calprotectinmedicine.symptombusinessVasculitisPediatric Rheumatology Online Journal
researchProduct

Acute rheumatic fever prophylaxis in high-income countries: clinical observations from an Italian multicentre, retrospective study.

2019

Objective-The aim of the study is to evaluate the compliance rate to secondary prophylaxis and the presence of Rheumatic Heart Disease (RHD) in a cohort of Italian patients with Acute Rheumatic Fever (ARF). Methods-This is a multicentre retrospective study. Patients were divided into two groups according to the presence or absence at last follow-up of RHD. Clinical features, ARF recurrences and the rate of compliance to secondary prophylaxis were evaluated. Results-wo hundred and ninety patients were enrolled (137 females, 153 males). Carditis at onset was present in 244 patients (84.7%). At the end of follow-up, 173 patients showed RHD. Adherence to secondary prophylaxis was low in 26% of …

MaleprophylaxiDeveloped CountriesRheumatic Heart Diseaseacute rheumatic fever; prophylaxis; rheumatic heart diseaseCarditirheumatic heart diseaseAcute rheumatic feveracute rheumatic feverSettore MED/38 - Pediatria Generale E SpecialisticaItalyHumansFemaleprophylaxisProphylaxiRheumatic FeverAcute rheumatic fever Carditis Compliance Prophylaxis Rheumatic heart diseaseComplianceRetrospective StudiesClinical and experimental rheumatology
researchProduct

Additional file 2 of Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during S…

2021

Additional file 2: Appendix 2. Clinical comparison between Kawasaki Disease patients seen during SARS-CoV-2 epidemic and a Historical Cohort of Kawasaki Disease Patients.

hemic and lymphatic diseasescardiovascular diseasesskin and connective tissue diseases
researchProduct

Additional file 1 of Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during S…

2021

Additional file 1: Appendix 1.

researchProduct

Additional file 4 of Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during S…

2021

Additional file 4: Appendix 4. Clinical comparison between Kawasaki Disease patients seen during SARS-CoV-2 in high epidemic regions (Piedmont and Lombardy) and Kawasaki Disease Patients in low epidemic regions.

hemic and lymphatic diseasescardiovascular diseasesskin and connective tissue diseases
researchProduct

Additional file 5 of Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during S…

2021

Additional file 5: Appendix 5. Comparison of laboratory tests between Kawasaki Disease patients seen during SARS-CoV-2 in high epidemic regions (Piedmont and Lombardy) and Kawasaki Disease Patients in low epidemic regions.

hemic and lymphatic diseasescardiovascular diseasesskin and connective tissue diseases
researchProduct

Additional file 3 of Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during S…

2021

Additional file 3: Appendix 3. Laboratory comparison between Kawasaki Disease patients seen during SARS-CoV-2 epidemic and a Historical Cohort of Kawasaki Disease Patients.

hemic and lymphatic diseasescardiovascular diseasesskin and connective tissue diseases
researchProduct